Literature DB >> 20194707

Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.

Erdembileg Anuurad1, Zeynep Ozturk, Byambaa Enkhmaa, Thomas A Pearson, Lars Berglund.   

Abstract

CONTEXT: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is bound predominately to low-density lipoprotein and has been implicated as a risk factor for coronary artery disease (CAD).
OBJECTIVE: We investigated the association between Lp-PLA(2) and CAD in a biethnic African-American and Caucasian population.
DESIGN: Lp-PLA(2) mass, activity, and index, an integrated measure of mass and activity, and other cardiovascular risk factors were determined in 224 African-Americans and 336 Caucasians undergoing coronary angiography. MAIN OUTCOME MEASURES: We assessed the distribution of Lp-PLA(2) levels and determined the predictive role of Lp-PLA(2) as a risk factor for CAD.
RESULTS: Levels of Lp-PLA(2) mass and activity were higher among Caucasians compared with African-Americans (293 +/- 75 vs. 232 +/- 76 ng/ml, P < 0.001 for mass and 173 +/- 41 vs. 141 +/- 39 nmol/min/ml, P < 0.001 for activity, respectively). However, Lp-PLA(2) index was similar in the two groups (0.61 +/- 0.17 vs. 0.64 +/- 0.19, P = NS). In both ethnic groups, Lp-PLA(2) activity and index was significantly higher among subjects with CAD. African-American subjects with CAD had significantly higher Lp-PLA(2) index than corresponding Caucasian subjects (0.69 +/- 0.20 vs. 0.63 +/- 0.18, P = 0.028). In multivariate regression analyses, after adjusting for other risk factors, Lp-PLA(2) index was independently (odds ratio 6.7, P = 0.047) associated with CAD in African-Americans but not Caucasians.
CONCLUSIONS: Lp-PLA(2) activity and index was associated with presence of CAD among African-Americans and Caucasians undergoing coronary angiography. The findings suggest an independent impact of vascular inflammation among African-Americans as contributory to CAD risk and underscore the importance of Lp-PLA(2) as a cardiovascular risk factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194707      PMCID: PMC2869550          DOI: 10.1210/jc.2009-2498

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

1.  Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).

Authors:  A I Adler; J C Levy; D R Matthews; I M Stratton; G Hines; R R Holman
Journal:  Diabet Med       Date:  2005-03       Impact factor: 4.359

2.  Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol.

Authors:  Erdembileg Anuurad; Jill Rubin; Guijing Lu; Thomas A Pearson; Steve Holleran; Rajasekhar Ramakrishnan; Lars Berglund
Journal:  J Lipid Res       Date:  2006-08-03       Impact factor: 5.922

Review 3.  Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Authors:  Carolina A Garza; Victor M Montori; Joseph P McConnell; Virend K Somers; Iftikhar J Kullo; Francisco Lopez-Jimenez
Journal:  Mayo Clin Proc       Date:  2007-02       Impact factor: 7.616

4.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

5.  Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

Authors:  Karl Winkler; Michael M Hoffmann; Bernhard R Winkelmann; Isolde Friedrich; Günther Schäfer; Ursula Seelhorst; Britta Wellnitz; Heinrich Wieland; Bernhard O Boehm; Winfried März
Journal:  Clin Chem       Date:  2007-06-15       Impact factor: 8.327

6.  Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.

Authors:  Curt D Furberg; Jeanenne J Nelson; Cam Solomon; Mary Cushman; Nancy Swords Jenny; Bruce M Psaty
Journal:  J Am Geriatr Soc       Date:  2008-03-21       Impact factor: 5.562

7.  Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.

Authors:  Vasilios G Saougos; Afroditi P Tambaki; Mihalis Kalogirou; Michael Kostapanos; Irene F Gazi; Robert L Wolfert; Moses Elisaf; Alexandros D Tselepis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-26       Impact factor: 8.311

8.  Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.

Authors:  Shahar Lavi; Joseph P McConnell; Charanjit S Rihal; Abhiram Prasad; Verghese Mathew; Lilach O Lerman; Amir Lerman
Journal:  Circulation       Date:  2007-05-14       Impact factor: 29.690

9.  Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.

Authors:  C Ballantyne; M Cushman; B Psaty; C Furberg; K T Khaw; M Sandhu; J Oldgren; G P Rossi; G Maiolino; M Cesari; L Lenzini; S K James; E Rimm; R Collins; J Anderson; W Koenig; H Brenner; D Rothenbacher; G Berglund; M Persson; P Berger; E Brilakis; J P McConnell; W Koenig; R Sacco; M Elkind; P Talmud; E Rimm; C P Cannon; C Packard; E Barrett-Connor; A Hofman; I Kardys; J C M Witteman; M Criqui; J P Corsetti; D L Rainwater; A J Moss; S Robins; H Bloomfield; D Collins; C Packard; S Wassertheil-Smoller; P Ridker; C Ballantyne; C P Cannon; M Cushman; J Danesh; D Gu; A Hofman; J J Nelson; S Thompson; A Zalewski; N Zariffa; E Di Angelantonio; S Kaptoge; A Thompson; S Thompson; M Walker; S Watson; A Wood
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-02

10.  Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men.

Authors:  Aiman El-Saed; Akira Sekikawa; Riad Wahid Zaky; Takashi Kadowaki; Tomoko Takamiya; Tomonori Okamura; Daniel Edmundowicz; Yoshikuni Kita; Lewis H Kuller; Hirotsugu Ueshima
Journal:  J Epidemiol       Date:  2007-11       Impact factor: 3.211

View more
  7 in total

1.  Age as a modulator of inflammatory cardiovascular risk factors.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Zeynep Gungor; Wei Zhang; Russell P Tracy; Thomas A Pearson; Kyoungmi Kim; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-23       Impact factor: 8.311

2.  Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk.

Authors:  Zeynep Gungor; Erdembileg Anuurad; Byambaa Enkhmaa; Wei Zhang; Kyoungmi Kim; Lars Berglund
Journal:  Atherosclerosis       Date:  2012-05-08       Impact factor: 5.162

3.  Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum.

Authors:  Li-Min Feng; Guo-Fang Feng; Yu Chen
Journal:  Lipids Health Dis       Date:  2014-01-07       Impact factor: 3.876

Review 4.  Obesity and lifespan health--importance of the fetal environment.

Authors:  Alice F Tarantal; Lars Berglund
Journal:  Nutrients       Date:  2014-04-24       Impact factor: 5.717

5.  Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden.

Authors:  Anuurad Erdembileg; Annie Mirsoian; Byambaa Enkhmaa; Wei Zhang; Laurel A Beckett; William J Murphy; Lars F Berglund
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

Review 6.  A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT).

Authors:  Junpei Li; Tianyu Cao; Yaping Wei; Nan Zhang; Ziyi Zhou; Zhuo Wang; Jingyi Li; Yue Zhang; Sijia Wang; Ping Wang; Nannan Cheng; Lijing Ye; Minghui Li; Yu Yu; Congcong Ding; Ziheng Tan; Biming Zhan; Qiangqiang He; Huihui Bao; Yanqing Wu; Lishun Liu; Jianping Li; Xiping Xu; Xiaoshu Cheng; Xiao Huang
Journal:  Dis Markers       Date:  2021-08-09       Impact factor: 3.434

7.  Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial.

Authors:  Maria Detopoulou; Agathi Ntzouvani; Filio Petsini; Labrini Gavriil; Elizabeth Fragopoulou; Smaragdi Antonopoulou
Journal:  Biomolecules       Date:  2021-05-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.